Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: Use of a mixture model

British Journal of Psychiatry

Volumn 199, Issue 6, 2011, Pages 501-507

  Thase, Michael E ^a   Larsen, Klaus G ^b   Kennedy, Sidney H ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PLACEBO; SERTRALINE;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83455233795     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.111.093336     Document Type: Article

References (29)

1. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005; 331: 155-7. (Pubitemid 41003178)
2. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 2: 45.
3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60.
4. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53.
5. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-7. (Pubitemid 36871872)
6. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-6. (Pubitemid 34456361)
7. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44-9.
8. Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the Congress of the American Psychiatric Association, 17-22 May 2003, San Francisco, California. (http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?-file-id=scsr/ SCSR-SCT-MD-26-final.pdf).
9. Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 2004; 29 (suppl): S87.
10. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22: 40-5. (Pubitemid 34101291)
11. Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39: 145-50. (Pubitemid 39602638)
12. Bech P, Andersen H, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006; 39: 128-34. (Pubitemid 44199180)
13. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9. (Pubitemid 9136500)
14. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology 1992; 6: 39-48; discussion 49-63.
15. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9-21. (Pubitemid 32642825)
16. McLachlan GJ, Peel D. Finite Mixture Models. Wiley, 2000.
17. Zhang B, Mitchell SL, Bambauer KZ, Jones R, Prigerson HG. Depressive symptom trajectories and associated risks among bereaved Alzheimer disease caregivers. Am J Geriatr Psychiatry 2008; 16: 145-5.
18. Larsen K. Joint analysis of time-to-event and multiple binary indicators of latent classes. Biometrics 2004; 60: 85-92. (Pubitemid 38392619)
19. Akaike H. Information theory as an extension of the maximum likelihood principle. In Second International Symposium on Information Theory (eds BN Petrov, F Csaki): 267-81. Akademiai Kiado, 1973.
20. Kasper S, de Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005; 13: 884-91. (Pubitemid 46638677)
21. Thase ME. Methodology to measure onset of action. J Clin Psychiatry 2001; 62 (suppl 15): 18-21. (Pubitemid 32601344)
22. Mayer D. Essential Evidence-based Medicine: 117. Cambridge University Press, 2004.
23. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevent Treat 2002; 5: 23.
24. Uher R, Muthén B, Souery D, Mors O, Jaracz J, Placentino A, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychol Med 2010; 40: 1367-77.
25. National Institute for Health and Clinical Excellence. Depression: The Treatment and Management of Depression in Adults. National Clinical Practice Guideline CG90. NICE, 2009 (http://www.nice.org.uk/CG90fullguideline.pdf).
26. Cohen J. Statistical Power Analysis for the Behavioural Sciences: 532. Erlbaum, 1988.
27. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009; 25: 161-75.
28. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
29. Box GEP, Draper NR. Empirical Model-Building and Response Surfaces: 424. Wiley, 1987.